Just In
- 4 hrs ago New Book ‘Kathmandu Chronicle: Reclaiming India-Nepal Relations’ To Shed Light On Geopolitical Uncertainties
- 8 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 10 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 11 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
Don't Miss
- Movies When Aishwarya Rai Gives ‘Classy Slap’ On Journalist’s Face For Asking Her To Pose Nude, Watch Video
- Sports KKR vs RCB: Twitter Hails as Virat Kohli and Gautam Gambhir Spotted having 'Friendly' Chat
- Education Assam Class 10 Result 2024 Declared: Anurag Emerged as the Top Performer With 593 Marks
- Finance 2 Tata Group Dividend Stocks To Buy/Sell After Q4 Results, Dividend Announcement
- News Bengaluru Water Crisis: PM Modi Slams Karnataka Congress, Says Mismanagement Turned Tech City To Tanker City
- Automobiles Tata Altroz Records a 55% Sales Growth in March 2024
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
WHO Publishes First Ebola Treatment Guideline
The Ebola virus disease (EVD) is a fatal disease with occasional outbreaks on the African continent. Most commonly, EVD affects humans and nonhuman primates (such as monkeys, gorillas, and chimpanzees). It is caused by a group of viruses within the genus Ebolavirus.
World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, including recommendations for two monoclonal antibodies. A monoclonal antibody is produced by a single clone of cells or cell lines and is composed of identical antibody molecules [1].
These treatments remain difficult to obtain, particularly in areas with limited resources. However, these drugs should be available to patients in areas where there is an active outbreak of Ebola or where the risk of outbreaks is high or very likely.
WHO urges the international community to increase access to these lifesaving medicines.
WHO Publishes First Ebola Treatment Guideline
Previously, Ebola outbreaks and responses have demonstrated that early diagnosis and treatment with optimized supportive care, such as fluid replacement and treatment of symptoms, significantly improve survival rates.
Here are some important points:
- The World Health Organization has recommended two monoclonal antibody treatments, mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb), following a systematic review and meta-analysis of randomized clinical trials.
- All patients confirmed positive for Ebola virus disease can use the two recommended therapeutics due to their demonstrated benefits, including the elderly, pregnant and nursing women, children, and newborns born to mothers who have confirmed Ebola within the first seven days of their birth.
- Also, therapeutics such as ZMapp and Remdesivir is not recommended for use in treating patients [2].
- WHO guidelines apply only to Ebola virus disease caused by the Ebola virus, such as EBOV and Zaire ebolavirus [3].
- The new guidance complements clinical care guidance outlining the optimal supportive care Ebola patients should receive, such as administering the relevant tests, managing pain, nutrition, and co-infections, as well as other approaches to ensuring the patient's recovery.
"This therapeutic guide is a critical tool to fight Ebola. It will help reassure the communities, health care workers and patients that this life-threatening disease can be treated thanks to effective drugs."
He continued, "From now on, people infected with the Ebola virus will have a greater chance of recovering if they seek care as early as possible. As with other infectious diseases, timeliness is key, and people should not hesitate to consult health workers as quickly as possible to ensure they receive the best care possible," said Dr Richard Kojan, co-chair of the Guideline Development Group of experts selected by WHO [4].
On A Final Note...
As part of its commitment to improving access to these treatments, WHO is prepared to support countries, manufacturers and partners, as well as national and global efforts to increase the affordability of biotherapeutics and similar biotherapeutics.
To improve access to drugs for communities and countries affected by Ebola, WHO has published the first invitation to therapeutics manufacturers against the Ebola virus to share their drugs with the WHO Prequalification Unit for evaluation.
- disorders cureFirst Death Confirmed In UK From New Outbreak; Know About Lassa Fever And Its Symptoms, Risks And Treatment
- disorders cureEverything You Need To Know About Fever, Dengue Fever, Ebola, Chikungunya And Typhoid Fever
- disorders cureDisease X, A New Disease Similar To COVID-19 And Ebola: Everything You Need To Know
- disorders cureChapare Virus: Human-To-Human Transmission Of Deadly Ebola-like Virus Confirmed
- wellnessWorld Toilet Day 2020: Infections You Can Catch From A Dirty Toilet
- disorders cure15 Warning Signs And Symptoms Of Ebola Virus Disease
- wellnessCan Ebola Virus Disease Be Prevented?
- newsEbola Outbreak In Congo, WHO Declares Global Health Emergency
- healthEris Variant: WHO Alarms New Covid Wave; Should India Be Concerned About This Pandemic
- healthDiet Coke Declared Cancerous By WHO: 5 Important Points; What To Drink Instead
- healthWorld Food Safety Day: WHO Ten Keys To Ensuring Food Safety
- healthEar-Safety Habits By WHO: Did You Know Sharing Your Earphones Is A Big No-No?